13 terminated. 13 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Terminated 13 |
Follow Amyloidosis: new trials by email Literature Review of Amyloidosis trials Research Report on Amyloidosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA) SAR445514 - Relapsed/Refractory Multiple Myeloma, Amyloid Light-chain Amyloidosis | Phase 1 | Terminated | Sanofi | 32 | 2023-05-15 | 2026-05-27 |
| A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis Melphalan-Flufenamide (Melflufen), Dexamethasone - AL Amyloidosis | Phase 1 | Terminated | Oncopeptides AB | 6 | 2020-08-06 | 2022-03-28 |
| Multiple Ascending Dose Study in Healthy Subjects NPT189 - Amyloidosis | Phase 1 | Terminated | Proclara Biosciences, Inc. | 8 | 2019-03-06 | 2019-08-19 |
| Biodistribution of 89Zirconium-labelled GSK2398852 Using PET Imaging GSK2315698 (CPHPC), GSK2398852 (unlabeled anti-SAP mAb), 89Zr-GSK2398852 (89Zr-labeled anti-SAP mAb) - Amyloidosis | Phase 1 | Terminated | GlaxoSmithKline | 2 | 2018-04-06 | 2019-08-29 |
| A Study of PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis PRX004 - Amyloidogenic Transthyretin (ATTR) Amyloidosis | Phase 1 | Terminated | Prothena Biosciences Limited | 21 | 2018-04-05 | 2020-08-20 |
| Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis Venetoclax, Dexamethasone - AL Amyloidosis | Phase 1 | Terminated | Tufts Medical Center | 3 | 2017-01-01 | 2020-08-21 |
| A Safety Study of GSK3039294 in Healthy Volunteers and Patients With Systemic Amyloidosis GSK3039294 - Amyloidosis | Phase 1 | Terminated | GlaxoSmithKline | 23 | 2016-05-12 | 2019-09-23 |
| Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis Pomalidomide, Melphalan, Dexamethasone - Myeloma | Phase 1 | Terminated | M.D. Anderson Cancer Center | 3 | 2014-01-01 | 2016-05-13 |
| First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD pomalidomide, bortezomib, dexamethasone - Light Chain Deposition Disease, Primary Systemic Amyloidosis | Phase 1 | Terminated | Barbara Ann Karmanos Cancer Institute | 18 | 2013-03-01 | 2023-05-09 |
| Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation filgrastim, amifostine trihydrate, melphalan - Drug/Agent Toxicity by Tissue/Organ, Multiple Myeloma and Plasma Cell Neoplasm | Phase 1 | Terminated | Eastern Cooperative Oncology Group | 8 | 2004-01-22 | 2023-06-18 |
| Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis 4'-iodo-4'-deoxydoxorubicin, pharmacological study - Primary Systemic Amyloidosis | Phase 1 | Terminated | National Cancer Institute (NCI) | 22 | 2001-12-01 | 2013-01-16 |
| 506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment Compound 506U78 - Chronic Myeloproliferative Disorders, Leukemia | Phase 1 | Terminated | Alliance for Clinical Trials in Oncology | 10 | 1999-12-01 | 2016-07-04 |
| 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder tetradecanoylphorbol acetate - Chronic Myeloproliferative Disorders, Leukemia | Phase 1 | Terminated | University of Medicine and Dentistry of New Jersey | 1998-12-01 | 2010-01-26 |
Immunoglobulin Light-chain Amyloidosis (9) · Multiple Myeloma (4) · Neoplasms, Plasma Cell (4) · Burkitt Lymphoma (2) · Hodgkin Disease (2) · Leukemia (2) · Leukemia, Hairy Cell (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Leukemia, Myeloid, Acute (2) · Leukemia, Myelomonocytic, Chronic (2) · Leukemia, Prolymphocytic (2) · Lymphoma (2) · Lymphoma, Follicular (2) · Lymphoma, Large B-Cell, Diffuse (2)
Metabolic Diseases (13) · Nutritional and Metabolic Diseases (13) · Proteostasis Deficiencies (13) · Neoplasms (10) · Neoplasms by Histologic Type (10) · Immune System Diseases (9) · Immunoproliferative Disorders (9) · Lymphoproliferative Disorders (9) · Paraproteinemias (9) · Neoplasms, Plasma Cell (6) · Blood Protein Disorders (4) · Cardiovascular Diseases (4) · Hematologic Diseases (4) · Hemic and Lymphatic Diseases (4)
Dexamethasone (4) · Calcium Dobesilate (3) · Melphalan (2) · pomalidomide (2) · 4'-deoxy-4'-iododoxorubicin (1) · Amifostine (1) · Bortezomib (1) · Filgrastim (1) · Immunoglobulin G (1) · Peripheral Blood Stem Cell Transplantation (1) · Surveys and Questionnaires (1) · Tetradecanoylphorbol Acetate (1) · dezamizumab (1) · melflufen (1) · miridesap (1)
GlaxoSmithKline (2) · Alliance for Clinical Trials in Oncology (1) · Barbara Ann Karmanos Cancer Institute (1) · Eastern Cooperative Oncology Group (1) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · Oncopeptides AB (1) · Proclara Biosciences, Inc. (1) · Prothena Biosciences Limited (1) · Sanofi (1) · Tufts Medical Center (1) · University of Medicine and Dentistry of New Jersey (1)
United States (9) · Spain (3) · United Kingdom (3) · Czechia (2) · Sweden (2) · Australia (1) · Belgium (1) · Canada (1) · France (1) · Germany (1) · Greece (1) · Hungary (1) · Israel (1) · Italy (1) · Netherlands (1)
Angela Dispenzieri (1) · Giovanni Palladini, MD (1) · Jeffrey Zonder (1) · Morie A. Gertz, MD (1) · Proclara Biosciences, Inc (1) · Raymond Comenzo, MD (1) · Robert Orlowski, MD, PHD (1) · Roger Strair, MD, PhD (1) · Todd M. Zimmerman, MD (1)
2017 (2), 2015 (1), P30CA072720 (1), U01CA069912 (1), U10CA021115 (1), U10CA031946 (1)